An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
Wednesday, May 13, 2015
8:00 AM – 3:30 PM
The most important advances in HIV research and clinical care in the last year will be summarized and presented by leading experts in the field, in a 1-day CME course setting. Click here to view the agenda.
Assessment of Needs
Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.
On completion of the course, participants will be able to:
- Apply new data to the prevention and management of HIV with antiretroviral therapy
- List resources in the Washington, DC, area, for identifying and linking high-risk HIV-infected populations to medical care
- Describe hepatitis C virus (HCV) infection screening, acute infection, and new drugs and treatment strategies for chronic HCV infection as well as drug-interactions, especially in HIV/HCV-coinfected patients on antiretroviral therapy
- Implement strategies for treating mental health issues in HIV-infected patients
- Recognize cardiovascular risk-factors and discuss updated recommendations concerning initiation and monitoring of statin therapy and potential interactions between statins and antiretroviral agents
- Discuss the current management of difficult opportunistic infections in patients not yet on ART including PML, cryptococcal meningitis, tuberculosis, and diarrhea
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection, specifically those who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV infection
- Are currently active in HIV research
This activity is also relevant for other practitioners including nurse practitioners, nurses, physician assistants, pharmacists, and others.
Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.
Cancellation and substitution requests must be made 8 or more days before the date of an activity. All refunds will be processed a week after the course minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Family Physicians Credits
This Live activity, 23rd Annual Improving the Management of HIV Disease Advanced CME Course, with a beginning date of 05/13/2015, has been reviewed and is acceptable for up to 6.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Education Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 6.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 6.5 hours (0.65 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-15-148-L01-P
This course is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Merck & Co, Inc
Additional support for select activity types in this national program is provided by: